Author/Authors :
Bowne, WilburB. Department of Surgery - Drexel University College of Medicine - Philadelphia - PA, USA , Platoff, RebeccaM. Department of Surgery - Drexel University College of Medicine - Philadelphia - PA, USA , Morano, WilliamF. Department of Surgery - Drexel University College of Medicine - Philadelphia - PA, USA , Marconcini, Luiz Department of Medicine - Division of Hematology/Oncology - Drexel University College of Medicine - Philadelphia - PA, USA , DeLeo, Nicholas Department of Surgery - Drexel University College of Medicine - Philadelphia - PA, USA , Styler, Michael Department of Surgery - Drexel University College of Medicine - Philadelphia - PA, USA , Mapow, BethL. Department of Pathology and Laboratory Medicine - Drexel University College of Medicine - Philadelphia - PA, USA
Abstract :
Recurrence of gastrointestinal stromal tumors (GISTs) after surgical resection and imatinib mesylate (IM) adjuvanttherapyposesasigni9canttreatmentchallenge.Wepresentthecaseofapatientwhounderwentsurgicalresectionafterrecurrenceandreview the current literature regarding treatment.Case Presentation. A 58-year-old man with a large intra-abdominal jejunal GISTwastreatedwithcompletesurgicalresectionfollowedbyIM..epatientexperienceddiseaserecurrence3.5yearslaterandunderwentIMdoseescalationandreresection.Conclusion.CurrentstrategiestotreatrecurrentGISTincludedoseescalation,modifyingadjuvanttyrosine kinase inhibitor therapy, and surgery. High-level evidence will be required to better de9ne the combinatory roles of tyrosinekinase inhibitor therapy, guided by molecular pro9ling, and surgery in the management of recurrent GIST
Keywords :
RecurrentGastrointestinalStromalTumors , ImatinibMesylateEra , TreatmentStrategies , IncurableDisease , Recurrence of gastrointestinal stromal tumors (GISTs)
